Alfacalcidol is a vitamin D analogue used for the management of hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in patients with chronic renal failure, as well as some types of rickets and osteomalacia.

Brand Names
Generic Name
DrugBank Accession Number

Alfacalcidol, or 1-alpha-hydroxycholecalciferol or 1-alpha-hydroxyvitamin D3, is a non-endogenous analogue of vitamin D.4 It plays an essential function in calcium homeostasis and bone metabolism. Alfacaldisol is activated by the enzyme 25-hydroxylase in the liver to mediate its effects in the body, or most importantly, the kidneys and bones. The pharmacological actions of alfacalcidol are prolonged than vitamin D because a negative feedback mechanism regulates the final activation step of vitamin D in the kidneys.1,2

Alfacalcidol is available in oral and intravenous formulations. In Canada, it is marketed as ONE-ALPHA, which manages hypocalcemia, secondary hyperparathyroidism, and osteodystrophy in adults with chronic renal failure.9 In approving European countries, alfacalcidol is also indicated for managing nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.11,12

Small Molecule
Approved, Nutraceutical
Average: 400.6371
Monoisotopic: 400.334130652
Chemical Formula
  • (5Z,7E)-9,10-seco-5,7,10(19)-cholestatrien-1α,3β-diol
  • 1-hydroxycholecalciferol
  • 1alpha-hydroxycholecalciferol
  • 1α-hydroxy-vitamin D3
  • 1α-hydroxycholecalciferol
  • 1α-hydroxyvitamin D3
  • 9,10-secocholesta-5,7,10(19)-triene-1α,3β-diol
  • Alfacalcidol
  • Alfacalcidolum



Alfacalcidol is indicated in adult patients with chronic renal failure for the management of hypocalcemia, secondary hyperparathyroidism, or osteodystrophy.9

Alfacalcidol is indicated in the management of nutritional and malabsorptive rickets and osteomalacia, vitamin D-dependent rickets and osteomalacia, and hypophosphataemic vitamin D resistant rickets and osteomalacia.11,12

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more

Alfacalcidol works to increase serum levels of calcium by stimulating intestinal calcium absorption, reabsorption of calcium from bone, and possibly the renal reabsorption of calcium. It also modestly promotes intestinal phosphorus absorption.9 In patients with renal failure, alfacalcidol increased intestinal calcium and phosphorus absorption in a dose-related manner. This increase in calcium and phosphorus levels occurs within three days following drug administration: this effect was reversed within three days of drug discontinuation. In patients with chronic renal failure, serum calcium levels were elevated while parathyroid hormone and alkaline phosphatase levels returned to normal levels within five days following alfacalcidol administration.12 Since alfacalcidol suppresses parathyroid hormone, a reduction in parathyroid hormone levels is achieved more rapidly in patients on intermittent intravenous therapy, with significant reductions occurring within three months of therapy. In patients receiving daily oral therapy of alfacalcidol, the time it takes alfacalcidol to normalize plasma calcium levels may be up to several months, possibly reflecting calcium being utilized for bone mineralization.9 In patients with nutritional osteomalacia, alfacalcidol increased calcium absorption with six hours of oral administration and the effects peaked at 24 hours.12

Mechanism of action

In conditions like chronic renal failure, renal bone disease, hypoparathyroidism, and vitamin D dependent rickets, the kidneys' capacity for 1α-hydroxylation is impaired, leading to reduced production of endogenous 1,25-dihydroxyvitamin D and aberrated mineral metabolism. As an active and potent analog of vitamin D, alfacalcidol works to restore the functions and activities of endogenous 1,25-dihydroxyvitamin D.12

AVitamin D3 receptor
U25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialNot AvailableHumans
URetinoic acid receptor RXR-alphaNot AvailableHumans

Alfacalcidol is absorbed passively and almost completely in the small intestine.12

Volume of distribution

Not Available

Protein binding

The active metabolite of alfacalcidol, 1,25-dihydroxyvitamin D, is transported to tissues via globulin, a specific transport protein.12


Alfacalcidol is rapidly converted in the liver to 1,25-dihydroxyvitamin D, which is essentially the metabolite of vitamin D that regulates calcium and phosphate metabolism. Alfacalcidol is further metabolized to other polar inactive metabolites, excreted primarily through the bile.12

Route of elimination

Not Available


The half-life of alfacalcidol ranges from three to four hours.9,12


Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more

There is a discrepancy across a number of reported LD50 values for alfacalcidol, which can be attributed to differences in the procedures used in laboratories. Oral LD50 in mice ranges from 440 to 490 mcg/kg. Intravenous in mice was 290 mcg/kg; however, another source presented 56 mcg/kg in female mice and 71 mcg/kg in male mice. Oral LD50 in rats ranges from 340 to 720 mcg/kg.9

In case of an acute accidental overdose following oral administration, emesis or gastric lavage can be induced to prevent further drug absorption. Mineral oil may be used to promote fecal drug elimination in instances where the drug was already absorbed in the stomach.9

Alfacalcidol overdose can lead to hypercalcemia, hypercalciuria, and hyperphosphatemia. Similarly, a high intake of calcium and phosphate concurrently with a therapeutic dose of alfacalcidol can result in those conditions.9 Hypercalcemia most commonly presents with headache, weakness, hypertension, somnolence, dizziness, sweating, anorexia, nausea, vomiting, diarrhea, constipation, polyuria, polydipsia and muscle and bone pain, and metallic taste.12 Hypercalcemia should be responded to with discontinuation of alfacalcidol, a low calcium diet and withdrawal of calcium supplements.9 Prolonged hypercalcemia can lead to nephrocalcinosis, nephrolithiasis, and reduced kidney function. In cases of severe hypercalcemia, general supportive measures are recommended, which may include forced diuresis and close monitoring of renal function, electrolytes, and electrocardiographs. Monitoring for abnormalities is especially critical in patients receiving digitalis glycosides. Management with glucocorticosteroids, loop diuretics, bisphosphonates, and calcitonin, as well as hemodialysis with low calcium content, may be considered.12

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AcetyldigitoxinThe risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Alfacalcidol is combined with Acetyldigitoxin.
Aluminum hydroxideThe serum concentration of Aluminum hydroxide can be increased when it is combined with Alfacalcidol.
Beclomethasone dipropionateThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Beclomethasone dipropionate.
BendroflumethiazideThe risk or severity of hypercalcemia can be increased when Bendroflumethiazide is combined with Alfacalcidol.
BenzthiazideThe risk or severity of hypercalcemia can be increased when Benzthiazide is combined with Alfacalcidol.
BetamethasoneThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Betamethasone.
Betamethasone phosphateThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Betamethasone phosphate.
BudesonideThe therapeutic efficacy of Alfacalcidol can be decreased when used in combination with Budesonide.
CalcifediolThe risk or severity of adverse effects can be increased when Calcifediol is combined with Alfacalcidol.
CalcitriolThe risk or severity of adverse effects can be increased when Calcitriol is combined with Alfacalcidol.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Take with or without food. Food does not affect the bioavailability.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Alsiodol / One Alpha
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Alfacalcidol CapsulesCapsule1 mcgOralStrides Pharma Canada IncNot applicableNot applicableCanada flag
Alfacalcidol CapsulesCapsule0.25 mcgOralStrides Pharma Canada IncNot applicableNot applicableCanada flag
One-alphaSolution / drops2 mcg / mLOralCheplapharm Arzneimittel Gmbh2000-12-04Not applicableCanada flag
One-alphaCapsule0.5 mcgOralLeo PharmaNot applicableNot applicableCanada flag
One-alphaCapsule0.25 mcgOralCheplapharm Arzneimittel Gmbh1980-12-31Not applicableCanada flag
One-alphaSolution2 mcg / mLIntravenousCheplapharm Arzneimittel Gmbh2001-02-20Not applicableCanada flag
One-alphaCapsule1 mcgOralCheplapharm Arzneimittel Gmbh1980-12-31Not applicableCanada flag
One-alpha Sol 0.2mcg/mlLiquid.2 mcg / mLOralLeo Pharma1989-12-312000-12-04Canada flag
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Alfa-D 0.25mcg CapsuleCapsuleOralPAHANG PHARMACY SDN. BHD.2020-09-08Not applicableMalaysia flag
Alfa-D 1.00mcg CapsuleCapsuleOralPAHANG PHARMACY SDN. BHD.2020-09-08Not applicableMalaysia flag
Alfacip 0.25mcg capsuleCapsuleOralCIPLA MALAYSIA SDN BHD2020-09-08Not applicableMalaysia flag
Alfacip 1mcg capsuleCapsuleOralCIPLA MALAYSIA SDN BHD2020-09-08Not applicableMalaysia flag
Alfost 0.25mcg (Alfacalcidol Capsule)Capsule0.25 mcgOralNVS REGULATORY SERVICES SDN BHD2021-12-02Not applicableMalaysia flag
Alfost 0.5mcg (Alfacalcidol Capsule)Capsule0.5 mcgOralNVS REGULATORY SERVICES SDN BHD2021-12-02Not applicableMalaysia flag
Alfost 1.0mcg (Alfacalcidol Capsule)Capsule1.0 mcgOralNVS REGULATORY SERVICES SDN BHD2021-12-02Not applicableMalaysia flag
ALPHA D3 1 MCGCapsule1 mcgOralบริษัท ซิลลิค ฟาร์มา จำกัด จำกัด2019-08-29Not applicableThailand flag
BON-ONE TABLET 0.25MCGTablet0.25 MCGOralSOMEDICO SDN. BHD.2020-09-082021-12-12Malaysia flag
BON-ONE TABLET 0.5MCGTablet0.5 MCGOralSOMEDICO SDN. BHD.2020-09-082021-12-12Malaysia flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
TEVABONE 70MG12TAB+1UG84KAAlfacalcidol (1 mcg) + Alendronic acid (70 mg)Tablet2014-07-01Not applicableGermany flag
TEVABONE 70MG4TAB+1UG28KAPAlfacalcidol (1 mcg) + Alendronic acid (70 mg)Tablet2014-07-01Not applicableGermany flag


ATC Codes
A11CC03 — AlfacalcidolM05BB06 — Alendronic acid and alfacalcidol, sequential
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as vitamin d and derivatives. These are compounds containing a secosteroid backbone, usually secoergostane or secocholestane.
Organic compounds
Super Class
Lipids and lipid-like molecules
Steroids and steroid derivatives
Sub Class
Vitamin D and derivatives
Direct Parent
Vitamin D and derivatives
Alternative Parents
Triterpenoids / Secondary alcohols / Cyclic alcohols and derivatives / Hydrocarbon derivatives
Alcohol / Aliphatic homopolycyclic compound / Cyclic alcohol / Hydrocarbon derivative / Organic oxygen compound / Organooxygen compound / Secondary alcohol / Triterpenoid
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
diol, seco-cholestane, D3 vitamins, hydroxycalciol (CHEBI:31186) / Vitamin D3 and derivatives (LMST03020231)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key


General References
  1. Galesanu C, Ciubotariu C, Melnic G, Galesanu MR: [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):833-41. [Article]
  2. Ringe JD, Schacht E: Improving the outcome of established therapies for osteoporosis by adding the active D-hormone analog alfacalcidol. Rheumatol Int. 2007 Dec;28(2):103-11. doi: 10.1007/s00296-007-0422-6. Epub 2007 Aug 1. [Article]
  3. Vervloet M: Clinical uses of 1-alpha-hydroxycholecalciferol. Curr Vasc Pharmacol. 2014 Mar;12(2):300-5. doi: 10.2174/15701611113119990132. [Article]
  4. Richy F, Deroisy R, Lecart MP, Hanssens L, Mawet A, Reginster JY: D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management. Aging Clin Exp Res. 2005 Apr;17(2):133-42. doi: 10.1007/BF03324586. [Article]
  5. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto T, Ogata E: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res. 2000 Apr;15(4):770-9. doi: 10.1359/jbmr.2000.15.4.770. [Article]
  6. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E: The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65(4):311-6. doi: 10.1007/s002239900704. [Article]
  7. O'Donnell S, Moher D, Thomas K, Hanley DA, Cranney A: Systematic review of the benefits and harms of calcitriol and alfacalcidol for fractures and falls. J Bone Miner Metab. 2008;26(6):531-42. doi: 10.1007/s00774-008-0868-y. Epub 2008 Nov 1. [Article]
  8. Schacht E, Richy F, Reginster JY: The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact. 2005 Jul-Sep;5(3):273-84. [Article]
  9. LEO Pharma Inc. Product Monograph: ONE-ALPHA (alfacalcidol), for oral and intravenous use [Link]
  10. Biosynth Carbosynth: Alfacalcidol Safety Data Sheet [Link]
  11. AIFA Package Leaflet: DEDIOL (Alfacalcidol) for oral and intravenous use [Link]
  12. Summary of Product Characteristics: Alfacalcidol Aristo oral capsules [Link]
Human Metabolome Database
PubChem Compound
PubChem Substance
PDBe Ligand
PDB Entries
FDA label
Download (123 KB)

Clinical Trials

Clinical Trials
4CompletedPreventionCardiac Valve Replacement Complication1
4CompletedTreatmentEnd Stage Renal Disease (ESRD) / Secondary Hyperparathyroidism (SHPT)1
4CompletedTreatmentFall / Osteopenia (Disorder) / Postmenopausal Osteoporosis1
4CompletedTreatmentSystemic Lupus Erythematosus (SLE)1
4CompletedTreatmentType 2 Diabetic Nephropathy1
4RecruitingTreatmentMinimal Change Disease / Nephrotic Syndrome1
4Unknown StatusTreatmentElderly Infection / Frail Elderly Syndrome1
4Unknown StatusTreatmentOsteoporosis1
4WithdrawnPreventionAgeing / Falls, Accidental / Renal Insufficiency,Chronic1
3CompletedPreventionGiant Cell Arteritis (GCA) / Granulomatosis With Polyangiitis / Polymyalgia Rheumatica (PMR) / Polymyositis / Rheumatoid Arthritis1


Not Available
Not Available
Dosage Forms
Solution / dropsOral
CapsuleOral0.25 UG
CapsuleOral0.5 UG
CapsuleOral1 UG
CapsuleOral1.0 UG
CapsuleOral1.0 mcg
Capsule, liquid filledOral0.25 cg
Capsule, liquid filledOral1 cg
TabletOral0.25 mcg
TabletOral0.5 mcg
TabletOral1 mcg
Injection, solutionIntravenous2 mcg/mL
Solution / dropsOral2 mcg/mL
Solution / dropsOral5 MCG/ML
SolutionOral2 UG/ML
CapsuleOral0.25 µg
Injection, solutionIntravenous1 µg/0.5mL
CapsuleOral1.0 µg
Injection, solutionIntravenous2 µg/mL
Solution / dropsOral2 MICROGRAMMI/1ML
Capsule, gelatin coatedOral
CapsuleOral1 mcg
CapsuleOral0.5 mcg
SolutionIntravenous2 mcg / mL
Solution / dropsOral2 mcg / mL
CapsuleOral0.25 mcg
Capsule, liquid filledOral0.25 mcg
Capsule, liquid filledOral1 mcg
Capsule, liquid filledOral0.5 mcg
SolutionOral2 mcg/ml
InjectionIntravenous2 mcg/ml
Injection, solutionIntravenous
LiquidOral.2 mcg / mL
CapsuleOral0.25 MICROGRAMMI
Unit descriptionCostUnit
One-Alpha 2 mcg/ml17.28USD ml
One-Alpha 2 mcg/ml Drops5.39USD ml
One-Alpha 1 mcg Capsule1.41USD capsule
One-Alpha 0.25 mcg Capsule0.47USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Not Available


Experimental Properties
melting point (°C)136 °CPhysProp
water solubility<1 mg/mL
Predicted Properties
Water Solubility0.00163 mg/mLALOGPS
pKa (Strongest Acidic)14.39Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area40.46 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity124.7 m3·mol-1Chemaxon
Polarizability50.56 Å3Chemaxon
Number of Rings3Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Human Intestinal Absorption+0.9865
Blood Brain Barrier+0.9142
Caco-2 permeable+0.7866
P-glycoprotein substrateSubstrate0.7469
P-glycoprotein inhibitor INon-inhibitor0.5785
P-glycoprotein inhibitor IIInhibitor0.5574
Renal organic cation transporterNon-inhibitor0.7945
CYP450 2C9 substrateNon-substrate0.8188
CYP450 2D6 substrateNon-substrate0.8945
CYP450 3A4 substrateSubstrate0.7656
CYP450 1A2 substrateNon-inhibitor0.8249
CYP450 2C9 inhibitorNon-inhibitor0.8802
CYP450 2D6 inhibitorNon-inhibitor0.9434
CYP450 2C19 inhibitorNon-inhibitor0.7466
CYP450 3A4 inhibitorNon-inhibitor0.8596
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5436
Ames testNon AMES toxic0.9077
BiodegradationNot ready biodegradable0.9944
Rat acute toxicity4.6023 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7959
hERG inhibition (predictor II)Non-inhibitor0.8176
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Zinc ion binding
Specific Function
Nuclear hormone receptor. Transcription factor that mediates the action of vitamin D3 by controlling the expression of hormone sensitive genes. Recruited to promoters via its interaction with BAZ1B...
Gene Name
Uniprot ID
Uniprot Name
Vitamin D3 receptor
Molecular Weight
48288.64 Da
  1. Reinhart GA: Vitamin D analogs: novel therapeutic agents for cardiovascular disease? Curr Opin Investig Drugs. 2004 Sep;5(9):947-51. [Article]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
  3. Fujishima T, Tsuji G, Tanaka C, Harayama H: Novel vitamin D receptor ligands having a carboxyl group as an anchor to arginine 274 in the ligand-binding domain. J Steroid Biochem Mol Biol. 2010 Jul;121(1-2):60-2. doi: 10.1016/j.jsbmb.2010.04.020. Epub 2010 May 6. [Article]
Pharmacological action
General Function
Iron ion binding
Specific Function
Catalyzes the conversion of 25-hydroxyvitamin D3 (25(OH)D) to 1-alpha,25-dihydroxyvitamin D3 (1,25(OH)2D) plays an important role in normal bone growth, calcium metabolism, and tissue differentiation.
Gene Name
Uniprot ID
Uniprot Name
25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrial
Molecular Weight
56503.475 Da
  1. Uchida E, Kagawa N, Sakaki T, Urushino N, Sawada N, Kamakura M, Ohta M, Kato S, Inouye K: Purification and characterization of mouse CYP27B1 overproduced by an Escherichia coli system coexpressing molecular chaperonins GroEL/ES. Biochem Biophys Res Commun. 2004 Oct 15;323(2):505-11. [Article]
Pharmacological action
Curator comments
Partial agonist.
General Function
Zinc ion binding
Specific Function
Receptor for retinoic acid. Retinoic acid receptors bind as heterodimers to their target response elements in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expressi...
Gene Name
Uniprot ID
Uniprot Name
Retinoic acid receptor RXR-alpha
Molecular Weight
50810.835 Da
  1. Zhang J, Chalmers MJ, Stayrook KR, Burris LL, Garcia-Ordonez RD, Pascal BD, Burris TP, Dodge JA, Griffin PR: Hydrogen/deuterium exchange reveals distinct agonist/partial agonist receptor dynamics within vitamin D receptor/retinoid X receptor heterodimer. Structure. 2010 Oct 13;18(10):1332-41. doi: 10.1016/j.str.2010.07.007. [Article]


Pharmacological action
General Function
Vitamin transporter activity
Specific Function
Involved in vitamin D transport and storage, scavenging of extracellular G-actin, enhancement of the chemotactic activity of C5 alpha for neutrophils in inflammation and macrophage activation.
Gene Name
Uniprot ID
Uniprot Name
Vitamin D-binding protein
Molecular Weight
52963.025 Da
  1. Nykjaer A, Dragun D, Walther D, Vorum H, Jacobsen C, Herz J, Melsen F, Christensen EI, Willnow TE: An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell. 1999 Feb 19;96(4):507-15. [Article]
  2. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C: A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol. 2002 Feb;9(2):131-6. [Article]
  3. Houghton LA, Vieth R: The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr. 2006 Oct;84(4):694-7. [Article]
  4. Yamamoto N, Naraparaju VR: Vitamin D3-binding protein as a precursor for macrophage activating factor in the inflammation-primed macrophage activation cascade in rats. Cell Immunol. 1996 Jun 15;170(2):161-7. [Article]
  5. Yamamoto N, Naraparaju VR: Role of vitamin D3-binding protein in activation of mouse macrophages. J Immunol. 1996 Aug 15;157(4):1744-9. [Article]
Pharmacological action
General Function
Not Available
Specific Function
Heme binding
Gene Name
Not Available
Uniprot ID
Uniprot Name
Alpha globin
Molecular Weight
13582.405 Da
  1. LEO Pharma Inc. Product Monograph: ONE-ALPHA (alfacalcidol), for oral and intravenous use [Link]
  2. Summary of Product Characteristics: Alfacalcidol Aristo oral capsules [Link]

Drug created at July 26, 2007 12:34 / Updated at December 03, 2022 06:44